134 related articles for article (PubMed ID: 34247906)
1. Prognostic relevance of ABO blood group system in non-metastatic renal cell carcinoma: An analysis of two independent European cohorts with long-term follow-up.
Barth DA; Sareban N; Lindner AK; Daller LAJ; Matzhold EM; Hutterer G; Smolle M; Mischinger J; Riedl JM; Seles M; Mannweiler S; Bauernhofer T; Pummer K; Pichler R; Zigeuner R; Schlenke P; Pichler M
Urol Oncol; 2021 Oct; 39(10):736.e9-736.e16. PubMed ID: 34247906
[TBL] [Abstract][Full Text] [Related]
2. ABO blood group is a predictor of survival in patients undergoing surgery for renal cell carcinoma.
Kaffenberger SD; Morgan TM; Stratton KL; Boachie AM; Barocas DA; Chang SS; Cookson MS; Herrell SD; Smith JA; Clark PE
BJU Int; 2012 Dec; 110(11 Pt B):E641-6. PubMed ID: 22958439
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of ABO blood group in patients with renal cell carcinoma: single-institution results from a large cohort.
Lee C; You D; Sohn M; Jeong IG; Song C; Kwon T; Hong B; Hong JH; Ahn H; Kim CS
J Cancer Res Clin Oncol; 2015 Aug; 141(8):1441-7. PubMed ID: 25687379
[TBL] [Abstract][Full Text] [Related]
4. Prognostic Significance of Blood Type A in Patients with Renal Cell Carcinoma.
Ko K; Park YH; Jeong CW; Ku JH; Kim HH; Kwak C
Urol J; 2016 Aug; 13(4):2765-72. PubMed ID: 27576883
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of ABO blood group as a prognostic marker in renal cell carcinoma (RCC).
de Martino M; Waldert M; Haitel A; Schatzl G; Shariat SF; Klatte T
BJU Int; 2014 May; 113(5b):E62-6. PubMed ID: 24053513
[TBL] [Abstract][Full Text] [Related]
6. Preoperative Measurement of the Modified Glasgow Prognostic Score Predicts Patient Survival in Non-Metastatic Renal Cell Carcinoma Prior to Nephrectomy.
Tsujino T; Komura K; Matsunaga T; Yoshikawa Y; Takai T; Uchimoto T; Saito K; Tanda N; Oide R; Minami K; Uehara H; Jeong SH; Taniguchi K; Hirano H; Nomi H; Ibuki N; Takahara K; Inamoto T; Azuma H
Ann Surg Oncol; 2017 Sep; 24(9):2787-2793. PubMed ID: 28643013
[TBL] [Abstract][Full Text] [Related]
7. High plasma fibrinogen level represents an independent negative prognostic factor regarding cancer-specific, metastasis-free, as well as overall survival in a European cohort of non-metastatic renal cell carcinoma patients.
Pichler M; Hutterer GC; Stojakovic T; Mannweiler S; Pummer K; Zigeuner R
Br J Cancer; 2013 Sep; 109(5):1123-9. PubMed ID: 23922109
[TBL] [Abstract][Full Text] [Related]
8. The Association Between Small Primary Tumor Size and Prognosis in Metastatic Renal Cell Carcinoma: Insights from Two Independent Cohorts of Patients Who Underwent Cytoreductive Nephrectomy.
DiNatale RG; Xie W; Becerra MF; Silagy AW; Attalla K; Sanchez A; Mano R; Marcon J; Blum KA; Benfante NE; Voss MH; Motzer RJ; Coleman J; Choueiri TK; Reznik E; Russo P; Heng DYC; Hakimi AA
Eur Urol Oncol; 2020 Feb; 3(1):47-56. PubMed ID: 31735646
[TBL] [Abstract][Full Text] [Related]
9. Chromophobe renal cell carcinoma (RCC): oncological outcomes and prognostic factors in a large multicentre series.
Volpe A; Novara G; Antonelli A; Bertini R; Billia M; Carmignani G; Cunico SC; Longo N; Martignoni G; Minervini A; Mirone V; Simonato A; Terrone C; Zattoni F; Ficarra V; ;
BJU Int; 2012 Jul; 110(1):76-83. PubMed ID: 22044519
[TBL] [Abstract][Full Text] [Related]
10. Validation of the pre-treatment neutrophil-lymphocyte ratio as a prognostic factor in a large European cohort of renal cell carcinoma patients.
Pichler M; Hutterer GC; Stoeckigt C; Chromecki TF; Stojakovic T; Golbeck S; Eberhard K; Gerger A; Mannweiler S; Pummer K; Zigeuner R
Br J Cancer; 2013 Mar; 108(4):901-7. PubMed ID: 23385728
[TBL] [Abstract][Full Text] [Related]
11. ABO blood group and risk of renal cell cancer.
Joh HK; Cho E; Choueiri TK
Cancer Epidemiol; 2012 Dec; 36(6):528-32. PubMed ID: 22841339
[TBL] [Abstract][Full Text] [Related]
12. Microvascular and lymphovascular tumour invasion are associated with poor prognosis and metastatic spread in renal cell carcinoma: a validation study in clinical practice.
Bedke J; Heide J; Ribback S; Rausch S; de Martino M; Scharpf M; Haitel A; Zimmermann U; Pechoel M; Alkhayyat H; Shariat SF; Dombrowski F; Stenzl A; Burchardt M; Klatte T; Kroeger N
BJU Int; 2018 Jan; 121(1):84-92. PubMed ID: 28803448
[TBL] [Abstract][Full Text] [Related]
13. Predicting recurrence and survival in patients with non-metastatic renal-cell carcinoma after nephrectomy: a prospective population-based study with multicenter validation.
Wang Y; Xuan Y; Su B; Gao Y; Fan Y; Huang Q; Zhang P; Gu L; Niu S; Shen D; Li X; Wang B; Zhu Q; Ouyang Z; Xie J; Ma X
Int J Surg; 2024 Feb; 110(2):820-831. PubMed ID: 38016139
[TBL] [Abstract][Full Text] [Related]
14. Effect of ABO blood type on the outcomes of patients with metastatic renal cell carcinoma treated with first-line tyrosine kinase inhibitors.
Omae K; Fukuma S; Ikenoue T; Kondo T; Takagi T; Ishihara H; Tanabe K; Fukuhara S
Urol Oncol; 2017 Sep; 35(9):540.e7-540.e12. PubMed ID: 28624136
[TBL] [Abstract][Full Text] [Related]
15. The Relationship Between Red Cell Distribution Width and Cancer-Specific Survival in Patients With Renal Cell Carcinoma Treated With Partial and Radical Nephrectomy.
Życzkowski M; Rajwa P; Gabrys E; Jakubowska K; Jantos E; Paradysz A
Clin Genitourin Cancer; 2018 Jun; 16(3):e677-e683. PubMed ID: 29339043
[TBL] [Abstract][Full Text] [Related]
16. Preoperative apolipoprotein B/A1 ratio is an independent prognostic factor in metastatic renal cell carcinoma.
Zhang F; Xie Y; Ma X; Gu L; Li H; Li X; Guo G; Zhang X
Urol Oncol; 2019 Mar; 37(3):184.e9-184.e17. PubMed ID: 30509867
[TBL] [Abstract][Full Text] [Related]
17. The prognostic role of preoperative serum albumin/globulin ratio in patients with non-metastatic renal cell carcinoma undergoing partial or radical nephrectomy.
Chung JW; Park DJ; Chun SY; Choi SH; Lee JN; Kim BS; Kim HT; Kim TH; Yoo ES; Byun SS; Hwang EC; Kang SH; Hong SH; Chung J; Kwak C; Kim YJ; Ha YS; Kwon TG
Sci Rep; 2020 Jul; 10(1):11999. PubMed ID: 32686760
[TBL] [Abstract][Full Text] [Related]
18. Increased preoperative levels of plasma fibrinogen and D dimer in patients with renal cell carcinoma is associated with poor survival and adverse tumor characteristics.
Erdem S; Amasyali AS; Aytac O; Onem K; Issever H; Sanli O
Urol Oncol; 2014 Oct; 32(7):1031-40. PubMed ID: 25027687
[TBL] [Abstract][Full Text] [Related]
19. Pre-existing type-2 diabetes is not an adverse prognostic factor in patients with renal cell carcinoma: a single-center retrospective study.
Antonelli A; Arrighi N; Corti S; Zanotelli T; Cozzoli A; Cosciani Cunico S; Simeone C
Urol Oncol; 2013 Oct; 31(7):1310-5. PubMed ID: 22281433
[TBL] [Abstract][Full Text] [Related]
20. The platelet to lymphocyte ratio predicts overall survival better than the neutrophil to lymphocyte ratio in metastatic renal cell carcinoma.
Aktepe OH; Güner G; Güven DC; Şahin TK; Ardıç FS; Yüce D; Yalçın Ş; Erman M
Turk J Med Sci; 2021 Apr; 51(2):757-765. PubMed ID: 33350295
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
